Pharmacy最新文献_第9页

Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs. 及时、廉价还是无风险？监管对新药价格和供应的影响》。

IF 2

Pharmacy Pub Date : 2024-03-18 DOI: 10.3390/pharmacy12020050

Laura Levaggi, Rosella Levaggi

引用次数: 0

Polypharmacy Is Associated with Sociodemographic Factors and Socioeconomic Status in United States Adults. 美国成年人的多重用药与社会人口因素和社会经济地位有关。

IF 2.2

Pharmacy Pub Date : 2024-03-12 DOI: 10.3390/pharmacy12020049

Vishal Vennu

{"title":"Polypharmacy Is Associated with Sociodemographic Factors and Socioeconomic Status in United States Adults.","authors":"Vishal Vennu","doi":"10.3390/pharmacy12020049","DOIUrl":"10.3390/pharmacy12020049","url":null,"abstract":"A thorough understanding of polypharmacy is required to create public health initiatives that minimize the potential for adverse outcomes. This study aimed to investigate the relationship between sociodemographic factors, socioeconomic status (SES), and polypharmacy risk in United States (US) individuals between 1999-2000 and 2017-2018. The cross-sectional National Health and Nutrition Examination Survey dataset covered ten cycles between 1999-2000 and 2017-2018. All individuals aged ≥18 years were included. The simultaneous use of at least five medications by one person is known as polypharmacy. Multivariable logistic regression showed that there was a statistically significant association between polypharmacy sociodemographic factors (such as age between 45 and 64 (odds ratio [OR] = 3.76; 95% confidence interval [CI] = 3.60-3.92; p < 0.0001) and age of 65 years or above (OR = 3.96; 95% CI = 3.79-4.13; p < 0.0001), especially women (OR = 1.09; 95% CI = 1.06-1.13; p < 0.0001), non-Hispanic blacks (OR = 1.66; 95% CI = 1.51-1.83; p < 0.0001), and veterans (OR = 1.27; 95% CI = 1.22-1.31; p < 0.0001)) and SES (such as being married (OR = 1.14; 95% CI = 1.08-1.19; p = 0.031), widowed, divorced, or separated (OR = 1.21; 95% CI = 1.15-1.26; p < 0.0001), a college graduate or above (OR = 1.21, 95% CI = 1.15-1.27, p < 0.0001), and earning > USD 55,000 per year (OR = 1.86; 95% CI = 1.79-1.93; p < 0.0001)). Individuals aged 45 years and above, women, and non-Hispanic blacks with higher educational levels and yearly incomes were more likely to experience polypharmacy in the US between 1999-2000 and 2017-2018.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients. 纳尔德美定和纳洛酮用于治疗癌症患者阿片类药物引起的便秘的系统性综述。

IF 2.2

Pharmacy Pub Date : 2024-03-06 DOI: 10.3390/pharmacy12020048

Ursula K Braun, Leanne K Jackson, Mary A Garcia, Syed N Imam

{"title":"A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients.","authors":"Ursula K Braun, Leanne K Jackson, Mary A Garcia, Syed N Imam","doi":"10.3390/pharmacy12020048","DOIUrl":"10.3390/pharmacy12020048","url":null,"abstract":"Background: Opioid-induced constipation (OIC) is a pervasive and distressing side effect of chronic opioid therapy in patients with cancer pain, significantly impacting their quality of life. Peripherally acting μ-opioid receptor antagonists (PAMORAS) were developed for treatment-resistant OIC but most studies were conducted with non-cancer patients.Objective: to discuss two oral formulations of PAMORAs, naldemedine and naloxegol, and to review available evidence of the effectiveness of these drugs for OIC in cancer patients.Methods: a comprehensive search to identify primary literature for either naldemedine or naloxegol for OIC in cancer patients.Results: Only three prospective randomized, double-blind, placebo-controlled clinical trials for naldemedine enrolling cancer patients were identified; the results of a subgroup analysis of two of those studies and two non-interventional post marketing surveillance studies of these trials are also reported here. For naloxegol, only two randomized controlled trials were identified; both were unsuccessful in enrolling sufficient patients. An additional four prospective non-interventional observational studies with naloxegol were found that enrolled cancer patients. There were significantly higher rates of responders in the PAMORA groups than in the placebo groups. The most common side effect for both PAMORAs was diarrhea.Limitations: All studies were industry-funded, and given that only three trials were randomized controlled studies, the overall quality of the studies was lacking.Conclusion: Naldemedine or naloxegol appeared safe and useful in the treatment of OIC in cancer patients and may improve their quality of life. Larger-scale randomized placebo-controlled studies of PAMORAs in cancer patients would strengthen existing evidence.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decreases and Pronounced Geographic Variability in Antibiotic Prescribing in Medicaid. 医疗补助中抗生素处方的减少和明显的地域差异。

IF 2.2

Pharmacy Pub Date : 2024-03-01 DOI: 10.3390/pharmacy12020046

Alexia G Aguilar, Priscilla C Canals, Maria Tian, Kimberly A Miller, Brian J Piper

{"title":"Decreases and Pronounced Geographic Variability in Antibiotic Prescribing in Medicaid.","authors":"Alexia G Aguilar, Priscilla C Canals, Maria Tian, Kimberly A Miller, Brian J Piper","doi":"10.3390/pharmacy12020046","DOIUrl":"10.3390/pharmacy12020046","url":null,"abstract":"Antibiotic resistance is a persistent and growing concern. Our objective was to analyze antibiotic prescribing in the United States (US) in the Medical Expenditure Panel System (MEPS) and to Medicaid patients. We obtained MEPS prescriptions for eight antibiotics from 2013 to 2020. We extracted prescribing rates per 1000 Medicaid enrollees for two years, 2018 and 2019, for four broad-spectrum (azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin) and four narrow-spectrum (amoxicillin, cephalexin, doxycycline, and trimethoprim-sulfamethoxazole) antibiotics. Antibiotic prescriptions in MEPS decreased from 2013 to 2020 by 38.7%, with a larger decline for the broad (-53.7%) than narrow (-23.5%) spectrum antibiotics. Antibiotic prescriptions in Medicaid decreased by 6.7%. Amoxicillin was the predominant antibiotic, followed by azithromycin, cephalexin, trimethoprim-sulfamethoxazole, doxycycline, ciprofloxacin, levofloxacin, and moxifloxacin. Substantial geographic variation in prescribing existed, with a 2.8-fold difference between the highest (Kentucky = 855/1000) and lowest (Oregon = 299) states. The South prescribed 52.2% more antibiotics (580/1000) than the West (381/1000). There were significant correlations across states (r = 0.81 for azithromycin and amoxicillin). This study identified sizable disparities by geography in the prescribing rates of eight antibiotics with over three-fold state-level differences. Areas with high prescribing rates, particularly for outpatients, may benefit from stewardship programs to reduce potentially unnecessary prescribing.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Assessment of Knowledge, Attitude, and Practice (KAP) of Colorectal Cancer among Community Pharmacists in the Qassim Region of Saudi Arabia. 评估沙特阿拉伯卡西姆地区社区药剂师对结直肠癌的认识、态度和实践 (KAP)。

IF 2.2

Pharmacy Pub Date : 2024-02-27 DOI: 10.3390/pharmacy12020042

Mohammed Alshammari, Saleh Al-Maktoum, Abdulrahman Alsharidah, Abubakar Siddique, Mohammed Anaam, Saud Alsahali, Yasser Almogbel, Ali Alkhoshaiban

{"title":"An Assessment of Knowledge, Attitude, and Practice (KAP) of Colorectal Cancer among Community Pharmacists in the Qassim Region of Saudi Arabia.","authors":"Mohammed Alshammari, Saleh Al-Maktoum, Abdulrahman Alsharidah, Abubakar Siddique, Mohammed Anaam, Saud Alsahali, Yasser Almogbel, Ali Alkhoshaiban","doi":"10.3390/pharmacy12020042","DOIUrl":"10.3390/pharmacy12020042","url":null,"abstract":"Background: The global burden of colorectal cancer remains a major public health issue and one of the leading causes of death worldwide. In Saudi Arabia, it continues to be a health concern. Any delays in diagnosis for any reason may contribute to advanced complications; therefore, pharmacists' knowledge and awareness of colorectal cancer are crucial for the welfare of society. Studies of colon cancer-related knowledge, attitude, and practice (KAP) among community pharmacists have not previously been conducted in the Al-Qassim region of Saudi Arabia. In the present study, therefore, we sought to investigate the KAP on colon cancer among pharmacists in Al-Qassim. Methods: This was a prospective, cross-sectional, observational study. A sample of 150 community pharmacists was recruited using a convenience sampling method. A self-administered questionnaire was used to evaluate levels of knowledge and practice. Results: Out of a total of 150 pharmacists, the majority of respondents (60.7%) possessed an adequate level of knowledge. About 50% of participants had heard of the early screening test, and 68.7% knew that colonoscopy is necessary in such scenarios. On the basis of their attitudes, 41.3% of study participants were aware of colon cancer symptoms and risk factors. In practice, however, the majority of pharmacists (81%) did not perform early cancer screenings, while 19% did screen when advised to do so by a physician. Conclusions: Our results indicate that pharmacists in Qassim have an adequate level of knowledge of colon cancer in terms of awareness, assessment, and screening. Since community pharmacists are among the most reliable members of the medical community, a greater awareness of colon cancer among pharmacists may improve public knowledge of the disease.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exogenous Melatonin Use in University Students: A Cross-Sectional Survey. 大学生使用外源性褪黑素的情况：一项横断面调查

IF 2.2

Pharmacy Pub Date : 2024-02-23 DOI: 10.3390/pharmacy12020041

Sulafa T Alqutub, Faris A Alzahrani, Abdulrahman S Hassan, Abdullah H Alirbidi, Osama A Alraddadi, Omar A AlSadah, Mohammad B Yamani, Mansour Tobaiqy

{"title":"Exogenous Melatonin Use in University Students: A Cross-Sectional Survey.","authors":"Sulafa T Alqutub, Faris A Alzahrani, Abdulrahman S Hassan, Abdullah H Alirbidi, Osama A Alraddadi, Omar A AlSadah, Mohammad B Yamani, Mansour Tobaiqy","doi":"10.3390/pharmacy12020041","DOIUrl":"10.3390/pharmacy12020041","url":null,"abstract":"To assess the prevalence of melatonin use and its perceived benefits among university students in different specialties in Saudi Arabia, a cross-sectional survey was conducted between March and June 2023. Data about demographics, time of melatonin use, perceived reasons for exogenous melatonin use, melatonin use in relation to exam periods, perceived safety, and adverse effects was gathered. Of 380 students, ~52% reported using exogenous melatonin for sleep disorders. Most participants reported using melatonin during and after exam periods. Additionally, several (n = 157; 75.4%) believed that its use was safe. The predominant use patterns were daily and as needed, and this study observed a higher rate of use compared with previous studies in Saudi Arabia. The most frequently reported adverse effect was headache (n = 36; 37.5%). A significant number of undergraduate male students in health specialties used melatonin. A high rate of melatonin use was noted during exam periods, which was attributed to sleep deprivation. Additionally, a significant number of students from private universities reported using exogenous melatonin. Melatonin use is common among university students. Future research should use a reliable psychometric measure to test its effect on university students' sleep quality and quantity.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacists' Attitudes towards Medically Assisted Dying. 药剂师对医疗协助死亡的态度。

IF 2.2

Pharmacy Pub Date : 2024-02-20 DOI: 10.3390/pharmacy12020040

Lun Shen Wong, Shane L Scahill, Emma Barton, Bert Van der Werf, Jessica Boey, Sanyogita Sanya Ram

{"title":"Pharmacists' Attitudes towards Medically Assisted Dying.","authors":"Lun Shen Wong, Shane L Scahill, Emma Barton, Bert Van der Werf, Jessica Boey, Sanyogita Sanya Ram","doi":"10.3390/pharmacy12020040","DOIUrl":"10.3390/pharmacy12020040","url":null,"abstract":"Aims: We aimed to explore pharmacists' attitudes and support toward medically assisted dying (MaiD) through the End of Life Choice Act 2019 (EOLC), their willingness to provide services in this area of practice, and the influences on their decisions.Methods: The study was conducted via an anonymous, online QualtricsTM survey of pharmacists. Registered New Zealand pharmacists who agreed to receive surveys from the two Schools of Pharmacy as part of their Annual Practicing Certificate renewal were invited to participate through an email with a Qualtrics URL link. The survey contained questions regarding demographics, awareness, knowledge, support for, and attitudes and willingness to participate.Results: Of the 335 responses received, 289 were valid and included in the analysis. Most participants supported legally assisted medical dying (58%), almost a third of participants did not support it (29%), and 13% of respondents were unsure. The five primary considerations that participants perceived to be beneficial included support from legislation, respect for patient autonomy, discussions around morality, ending suffering, and preserving dignity. The main concerns were legal, personal bias, palliation, stigmatisation, and vulnerability.Conclusions: The influences on the decision by pharmacists to support and willingness to participate in the provision of services consistent with the EOLC are complex and multifactorial. Diverse factors may influence attitudes, of which religion is the most significant factor in not supporting the Act or willingness to participate. Clarity and standardised guidance to ensure that assisted dying queries are appropriately managed in practice would help to address any potential access issues.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10885061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a Prediction Model to Identify the Risk of Clostridioides difficile Infection in Hospitalized Patients Receiving at Least One Dose of Antibiotics. 开发一种预测模型，以确定至少接受过一次抗生素治疗的住院患者感染艰难梭菌的风险。

IF 2.2

Pharmacy Pub Date : 2024-02-19 DOI: 10.3390/pharmacy12010037

Abdulrahman Alamri, AlHanoof Bin Abbas, Ekram Al Hassan, Yasser Almogbel

{"title":"Development of a Prediction Model to Identify the Risk of Clostridioides difficile Infection in Hospitalized Patients Receiving at Least One Dose of Antibiotics.","authors":"Abdulrahman Alamri, AlHanoof Bin Abbas, Ekram Al Hassan, Yasser Almogbel","doi":"10.3390/pharmacy12010037","DOIUrl":"10.3390/pharmacy12010037","url":null,"abstract":"Objective: This study's objective was to develop a risk-prediction model to identify hospitalized patients at risk of Clostridioides difficile infection (CDI) who had received at least one dose of systemic antibiotics in a large tertiary hospital.Patients and methods: This was a retrospective case-control study that included patients hospitalized for more than 2 days who received antibiotic therapy during hospitalization. The study included two groups: patients diagnosed with hospital CDI and controls without hospital CDI. Cases were matched 1:3 with assigned controls by age and sex. Descriptive statistics were used to identify the study population by comparing cases with controls. Continuous variables were stated as the means and standard deviations. A multivariate analysis was built to identify the significantly associated covariates between cases and controls for CDI.Results: A total of 364 patients were included and distributed between the two groups. The control group included 273 patients, and the case group included 91 patients. The risk factors for CDI were investigated, with only significant risks identified and included in the risk assessment model: age older than 70 years (p = 0.034), chronic kidney disease (p = 0.043), solid organ transplantation (p = 0.021), and lymphoma or leukemia (p = 0.019). A risk score of ≥2 showed the best sensitivity, specificity, and accuracy of 78.02%, 45.42%, and 78.02, respectively, with an area under the curve of 0.6172.Conclusion: We identified four associated risk factors in the risk-prediction model. The tool showed good discrimination that might help predict, identify, and evaluate hospitalized patients at risk of developing CDI.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10892393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medication Review: What's in a Name and What Is It about? 药物评论：名字里有什么？

IF 2.2

Pharmacy Pub Date : 2024-02-19 DOI: 10.3390/pharmacy12010039

Anneleen Robberechts, Maja Brumer, Victoria Garcia-Cardenas, Niurka M Dupotey, Stephane Steurbaut, Guido R Y De Meyer, Hans De Loof

{"title":"Medication Review: What's in a Name and What Is It about?","authors":"Anneleen Robberechts, Maja Brumer, Victoria Garcia-Cardenas, Niurka M Dupotey, Stephane Steurbaut, Guido R Y De Meyer, Hans De Loof","doi":"10.3390/pharmacy12010039","DOIUrl":"10.3390/pharmacy12010039","url":null,"abstract":"Background: Medication review is a multifaceted service aimed at optimizing the use of medicines and enhancing the health outcomes of patients. Due to its complexity, it is crucial to clearly describe the service, its variants, and its components to avoid confusion and ensure a better understanding of medication review among healthcare providers.Aim: This study aims to bring clarity to the origins, definitions, abbreviations, and types of medication reviews, together with the primary criteria that delineate key features of this service.Method: A narrative review approach was employed to clarify the diverse terminology associated with \"medication review\" services. Relevant references were initially identified through searches on PubMed and Google Scholar, complementing the existing literature known to the authors.Results: The study uncovers a complicated and sometimes convoluted history of \"medication review\" in different regions around the world. The initial optimization of medicine use had an economic purpose before evolving subsequently into a more patient-oriented approach. A selection of abbreviations, definitions, and types were outlined to enhance the understanding of the service.Conclusions: The study underscores the urgent need for comprehensive information and standardization regarding the content and quality of the services, collectively referred to as \"medication review\".","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10892708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two Cases of Vancomycin-Induced Neutropenia. 两例万古霉素诱发的中性粒细胞减少症

IF 2.2

Pharmacy Pub Date : 2024-02-19 DOI: 10.3390/pharmacy12010038

Kirsten Ganaja, Sarah Scoular, Staci Hemmer

{"title":"Two Cases of Vancomycin-Induced Neutropenia.","authors":"Kirsten Ganaja, Sarah Scoular, Staci Hemmer","doi":"10.3390/pharmacy12010038","DOIUrl":"10.3390/pharmacy12010038","url":null,"abstract":"(1) Background: The incidence of vancomycin-induced neutropenia in hospitalized patients is estimated to be around 2 to 8 percent Data surrounding vancomycin-induced neutropenia is limited as it is based on a small number of observational case reports. Additionally, it is difficult to provide generalized conclusions since patient characteristics and indications for treatment vary between reports. (2) Case Reports: We present two cases of vancomycin-induced neutropenia that occurred at our facility; a 50-year-old male who developed neutropenia after treatment with vancomycin for a gluteal abscess and a 51-year-old female who developed neutropenia after treatment with vancomycin for lumbar osteomyelitis. In both cases, neutropenia resolved within 2 days of discontinuation of vancomycin. (3) Conclusions: Vancomycin-induced neutropenia is thought to be a relatively uncommon adverse drug reaction. These two cases of neutropenia likely caused by prolonged exposure to vancomycin occurred at our facility within 3 months of each other. Additional studies are needed to better understand the true incidence of this adverse drug reaction and to identify risk factors that may predispose patients to vancomycin-induced neutropenia.","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0